Fenja Capital II A/S requests conversion of the remaining outstanding convertibles for a total nominal amount of SEK 6 million
26 juni, 17:30
On 15 February 2024, Saniona AB (“Saniona”) issued convertibles to Fenja Capital II A/S (previously Formue Nord Fokus A/S, “Fenja Capital”). After requested conversions in October and December 2024, Saniona’s outstanding convertibles to Fenja Capital amounted to SEK 6 million. Fenja Capital has now requested conversion of the remaining outstanding convertibles for a total nominal amount of SEK 6 million, whereby a total of 1,941,747 new shares are issued to Fenja Capital at a conversion price of SEK 3.09 per share.
As a result of the conversion of convertibles, the number of shares in Saniona will increase by 1,941,747, from 136,088,387 to 138,030,134. The share capital will thereby increase by SEK 97,087.35, from SEK 6,804,419.35 to SEK 6,901,506.70. Thus, the conversion entails a dilution effect of approximately 1.41 per cent of Saniona’s shares and votes.
For more information, please contact
Thomas Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.com
About Saniona
Saniona (OMX: SANION) is a clinical-stage biopharmaceutical company focused on neurological and psychiatric diseases. Its internal pipeline includes SAN2219 and SAN2355 for epilepsy and SAN2465 for major depressive disorder. Saniona has two strategic collaborations: one with Acadia Pharmaceuticals, which has licensed worldwide rights to ACP-711 and is preparing it for Phase 2 in essential tremor, and one with Productos Medix, which holds the rights to tesofensine for obesity in Mexico and Argentina and has submitted a market authorization application in Mexico. Saniona also has two clinical programs available for partnership: Tesomet™, ready for Phase 2b in rare eating disorders, and SAN903, ready for Phase 1 in inflammatory bowel disease. Saniona’s partners also include Boehringer Ingelheim, AstronauTx, and Cephagenix. Based in Copenhagen, Saniona is listed on Nasdaq Stockholm Main Market.
For more information, visit www.saniona.com.
Ämnen i artikeln
Fenja Capital II A/S requests conversion of the remaining outstanding convertibles for a total nominal amount of SEK 6 million
26 juni, 17:30
On 15 February 2024, Saniona AB (“Saniona”) issued convertibles to Fenja Capital II A/S (previously Formue Nord Fokus A/S, “Fenja Capital”). After requested conversions in October and December 2024, Saniona’s outstanding convertibles to Fenja Capital amounted to SEK 6 million. Fenja Capital has now requested conversion of the remaining outstanding convertibles for a total nominal amount of SEK 6 million, whereby a total of 1,941,747 new shares are issued to Fenja Capital at a conversion price of SEK 3.09 per share.
As a result of the conversion of convertibles, the number of shares in Saniona will increase by 1,941,747, from 136,088,387 to 138,030,134. The share capital will thereby increase by SEK 97,087.35, from SEK 6,804,419.35 to SEK 6,901,506.70. Thus, the conversion entails a dilution effect of approximately 1.41 per cent of Saniona’s shares and votes.
For more information, please contact
Thomas Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.com
About Saniona
Saniona (OMX: SANION) is a clinical-stage biopharmaceutical company focused on neurological and psychiatric diseases. Its internal pipeline includes SAN2219 and SAN2355 for epilepsy and SAN2465 for major depressive disorder. Saniona has two strategic collaborations: one with Acadia Pharmaceuticals, which has licensed worldwide rights to ACP-711 and is preparing it for Phase 2 in essential tremor, and one with Productos Medix, which holds the rights to tesofensine for obesity in Mexico and Argentina and has submitted a market authorization application in Mexico. Saniona also has two clinical programs available for partnership: Tesomet™, ready for Phase 2b in rare eating disorders, and SAN903, ready for Phase 1 in inflammatory bowel disease. Saniona’s partners also include Boehringer Ingelheim, AstronauTx, and Cephagenix. Based in Copenhagen, Saniona is listed on Nasdaq Stockholm Main Market.
For more information, visit www.saniona.com.
Ämnen i artikeln
-1-992x558.webp&w=3840&q=75)
-992x558.webp&w=3840&q=75)
-992x558.webp&w=3840&q=75)
Mest läst
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
-992x558.jpg&w=3840&q=75)